CSL News: Seqirus, a Business of CSL Limited, Announces New Facility Supporting Research & Development of Lead - 8th Feb 2022, 12:30am

[zeeb0t]

New facility in Waltham, Massachusetts, will support CSL's growing R&D portfolio, including the self-amplifying mRNA technology platform, the next generation of mRNA vaccine technology, for seasonal and pandemic influenza vaccines

SUMMIT, N.J., Feb. 7, 2022 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced an investment in a new Research and Development (R&D) facility located in Waltham, Mass. The new facility will support ...

>>> Read more: Seqirus, a Business of CSL Limited, Announces New Facility Supporting Research & Development of Leading-Edge Influenza Vaccine Technology

 

[Equitable]

New facility in Waltham, Massachusetts, will support CSL's growing R&D portfolio, including the self-amplifying mRNA technology platform, the next generation of mRNA vaccine technology, for seasonal and pandemic influenza vaccines

SUMMIT, N.J., Feb. 7, 2022 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced an investment in a new Research and Development (R&D) facility located in Waltham, Mass. The new facility will support ...

>>> Read more: Seqirus, a Business of CSL Limited, Announces New Facility Supporting Research & Development of Leading-Edge Influenza Vaccine Technology

Good to see CSL branching out into mRNA. Of course, their R&D is always seeking out something new and keeping the development pipeline full.